Loading
Chromosome changes such as del(17p), t(4;14), t(14;16) and extra copies of 1q that mark myeloma likely to relapse early.
IMS 2024 consensus: high risk = del(17p) with TP53 mutation or ≥20% clonal fraction, t(4;14) or t(14;16) or t(14;20) with 1q gain or del(1p), biallelic del(1p32), or β2M ≥5.5 with normal creatinine. Ultra-high risk with two or more lesions. High-risk patients gain less from most regimens; CAR-T and bispecifics narrow but do not close the gap.
In plain words · TP53 is the 'guardian of the genome', broken in half of all cancers. Fixing it directly has so far defeated every attempt, so drugs exploit what its loss makes cancers depend on.
Showing the target this term concerns: TP53.
Shares Multiple Myeloma Research Foundation (MMRF), Smouldering multiple myeloma, Ubiquitin-proteasome system & protein homeostasis, Newly diagnosed multiple myeloma, transplant-eligible.
Shares Multiple Myeloma Research Foundation (MMRF), Multiple myeloma.
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible, Multiple myeloma.
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Multiple myeloma.
Shares Ubiquitin-proteasome system & protein homeostasis, Multiple myeloma.
Shares Plasma cell leukaemia, Newly diagnosed multiple myeloma, transplant-eligible, Multiple myeloma.